Skoupilová Hana, Michalová Eva, Hrstka Roman
Klin Onkol. 2018 Winter;31(Suppl 2):21-26. doi: 10.14735/amko20182S21.
Ferroptosis is a recently discovered type of cell death. It is genetically, morphologically, and biochemically distinct from other types of programmed cell death, such as necrosis, apoptosis, and autophagy. The level of intracellular free iron and reactive oxygen species formation are important for ferroptosis activation, which can occur through either of two key inhibitory processes. The first one involves inhibition of cystine transfer into cells by the cystine/glutamate antiporter system (Xc-). Cystine serves as a precursor for the synthesis of glutathione, a major cellular antioxidant. The second one involves the inhibition of glutathione peroxidase 4, which protects cells from lipid peroxidation. Ferroptosis is associated with many metabolic disorders, including neurological diseases and cancer. Molecules involved in the activation of ferroptotic pathways are involved in protecting cells against stress conditions, and in the maintenance of nicotinamide adenine dinucleotide phosphate and glutathione levels, as well as iron homeostasis. Also important is the connection with autophagy, so called ferritinophagy, in which iron is released from lysosomes into the cytosol. Cascade reactions of free unstable iron atoms with other molecules result in the production of reactive oxygen species that initiate the cellular stress that triggers ferroptosis. In diseases such as cancer where cell death inducing mechanisms, including apoptosis, are usually suppressed by genetic changes, the induction of alternative pathways leading to cell death could provide an attractive treatment strategy.
In recent years, research into new antimetastatic drugs has focused on the activation of alternative cell death pathways that might overcome disturbed metabolic processes inside cancer cells or the chemotherapy resistance acquired in the course of routine treatment. A number of molecules have been found to induce ferroptosis in tumor cells, suggesting that they may offer new alternatives for anticancer treatment. Key words: cell death - cancer - autophagy - ferroptosis - ferritinophagy - cellular stress - ROS This work was supported by the projects GAČR 17-05838S, MEYS - NPS I - LO1413 and MH CZ- -DRO (MMCI, 00209805). The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Accepted: 31. 8. 2018.
铁死亡是最近发现的一种细胞死亡类型。在基因、形态和生化方面,它与其他类型的程序性细胞死亡不同,如坏死、凋亡和自噬。细胞内游离铁水平和活性氧的形成对于铁死亡的激活很重要,铁死亡可通过两个关键抑制过程中的任何一个发生。第一个过程涉及胱氨酸/谷氨酸反向转运体系统(Xc-)抑制胱氨酸转运进入细胞。胱氨酸是合成谷胱甘肽(一种主要的细胞抗氧化剂)的前体。第二个过程涉及抑制谷胱甘肽过氧化物酶4,该酶可保护细胞免受脂质过氧化作用。铁死亡与许多代谢紊乱有关,包括神经疾病和癌症。参与铁死亡途径激活的分子参与保护细胞免受应激条件影响,维持烟酰胺腺嘌呤二核苷酸磷酸和谷胱甘肽水平以及铁稳态。与自噬(即所谓的铁蛋白自噬,其中铁从溶酶体释放到细胞质中)的联系也很重要。游离不稳定铁原子与其他分子的级联反应导致活性氧的产生,从而引发细胞应激,进而触发铁死亡。在癌症等疾病中,包括凋亡在内的细胞死亡诱导机制通常会因基因变化而受到抑制,诱导导致细胞死亡的替代途径可能提供一种有吸引力的治疗策略。
近年来,对新型抗转移药物的研究集中在激活替代细胞死亡途径上,这些途径可能克服癌细胞内紊乱的代谢过程或常规治疗过程中获得的化疗耐药性。已发现许多分子可诱导肿瘤细胞发生铁死亡,这表明它们可能为抗癌治疗提供新的选择。关键词:细胞死亡 - 癌症 - 自噬 - 铁死亡 - 铁蛋白自噬 - 细胞应激 - 活性氧 本研究得到了GAČR 17 - 05838S、MEYS - NPS I - LO1413和MH CZ - DRO(MMCI,00209805)项目的支持。作者声明他们在研究中使用的药物、产品或服务不存在潜在利益冲突。编辑委员会声明该手稿符合ICMJE对生物医学论文的建议。接受日期:2018年8月31日。